Abstract
The effect of estrogen on compositional changes, apolipoprotein (apo) A-I metabolism and the morphology of plasma high density lipoprotein (HDL) were investigated in chicks. The administration of 17β-estradiol (25 mg/kg body weight) to growing male chicks (8-week-old) markedly reduced the concentrations of plasma HDL components, except for triglyceride (TG). At the same time, levels of TG, total cholesterol (TC) and phospholipid (PL) in plasma were greatly elevated. The respective values for TG, TC, PL and protein in HDL were 13.9, 89.3, 154.1 and 231.7 (mg/dL) in the control, and 39.0, 35.1, 113.8 and 160.0 (mg/dL) in chicks upon estrogen treatment for one day.In vivo kinetic studies showed that the fractional catabolic rate of HDL apo A-I was significantly higher (p<0.05) in estrogen-treated chicks than in control birds, indicating an increased efficiency of HDL removal in the former. The production rate of HDL apo A-I also was significantly lower (p<0.05) in estrogen-treated chicks. Sodium dodecyl sulfate-acrylamide gel electrophoresis followed by laser scanning densitometry of HDL apolipoproteins in estrogen-treated chicks revealed a reduction of apo A-I and the occurrence of new apolipoproteins which had been absent in HDL of untreated birds. The HDL particles showed that the mean particle size of HDL became larger upon estrogen treatment. Particles with diameters between 70 and 123 Å were predominant in HDL of control chicks, while particles with diameters between 97 and 143 Å were most abundant in HDL of estrogen-treated chicks.
Similar content being viewed by others
Abbreviations
- apo:
-
apolipoprotein
- EDTA:
-
ethylenediaminetetraacetic acid
- FCR:
-
fractional catabolic rate
- HDL:
-
high density lipoprotein
- LDL:
-
low density lipoprotein
- PL:
-
phospholipid
- SDS:
-
sodium dodecyl sulfate
- TC:
-
total cholesterol
- TG:
-
triglyceride
- VLDL:
-
very low density lipoprotein
References
Miller, N.E., Forde, O.H., Telle, D.S., and Mjos, O.D. (1977)Lancet 1, 965–967.
Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.B., and Dawber, T.R. (1977)Am. J. Med. 62, 707–714.
Daniels, R.J., Guertler, L.S., Parker, T.S., and Steinberg, D. (1981).J. Biol. Chem. 256, 4978–4983.
Oram, J.F., Albers, J.J., Cheung, M.C., and Bierman, E.L. (1981)J. Biol. Chem. 256, 8348–8356.
Heiss, G., Tamir, I., Davis, C.E., Tyroler, H.A., Rifkind, B.M., Schonfeld, G., Jacobs, D., and Frantz, I.D. (1980)Circulation 61, 302–315.
Krauss, R.M., Lindgren, F.T., Wingerd, J., Bradley, D.D., and Ramcharan, S. (1979)Lipids 14, 113–118.
Schaefer, E.J., Foster, D.M., Zech, L.A., Lindgren, F.T., Brewer, Jr., H.B., and Levy, R.I. (1983)J. Clin. Endocrinol. Metab. 57, 262–267.
Stalenhoef, A.F.H., Malloy, M.J., Kane, J.P., and Havel, R.J. (1986)J. Clin. Invest. 78, 722–728.
Wilson, D.E., and Lees, R.S. (1972)J. Clin. Invest. 51, 1051–1057.
Garrison, R.J., Kannel, W.B., Feinleib, M., Castelli, W.P., McNamara, P.M., and Padgett, S.J. (1978)Atherosclerosis 30, 17–25.
Shepherd, J., Packard, C.J., Patsch, J.R., Gotto, Jr., A.M., and Taunton, O.D. (1978)J. Clin. Invest. 61, 1582–1592.
Castelli, W.P., Doyle, J.T., Gordon, T., Hames, C.G., Hjortland, M.C., Hulley, S.B., Kagan, A., and Zukel, W.J. (1977)Lancet 2, 153–155.
Wood, P.D., and Haskell, W.L. (1979)Lipids 14, 417–427.
Cheung, M.C., Albers, J.J., Wahl, P.W., and Hazzard, W.R. (1980)Atherosclerosis 35, 215–228.
Tikkanen, M.J., Nikkila, E.A., Kussi, T., and Sipinen, S. (1982)J. Clin. Endocrinol. Metab. 54, 1113–1117.
Luskey, K.L., Brown, M.S., and Goldstein, J.L. (1974)J. Biol. Chem. 249, 5939–5947.
Park, J.R., and Cho, B.H.S. (1988)Lipids 23, 327–333.
Molitch, M.E., Oill, P., and Odell, W.D. (1974)J. Am. Med. Assoc. 227, 522–525.
Noble, R.P. (1968)J. Lipid Res. 9, 693–700.
Lowry, O.H., Rosebrough, N.J., Farr, A.L., and Randall, R.J. (1951)J. Biol. Chem. 193, 267–275.
Schacterle, G.R., and Pollack, R.L. (1973)Anal. Biochem. 51, 654–655.
McFarlane, A.S. (1963)J. Clin. Invest. 42, 346–361.
Fidge, N.H., and Poulis, P. (1974)Clin. Chim. Acta 52, 15–26.
Shipley, R.A., and Clark, R.E. (1972)Tracer Methods for in Vivo Kinetics: Theory and Applications, Academic Press, New York.
Laemmli, U.K. (1970)Nature 227, 680–685.
Foster, L.B., and Dunn, R.T. (1973)Clin. Chem. 19, 338–340.
Eng, L.F., and Noble, E.P. (1968)Lipids 3, 157–162.
Berkson, D.M., Stamler, J., and Cohen, D.B. (1964)Clin. Obstet. Gynecol. 17, 504–530.
Kuusi, T., Saarinen, P., and Nikkila, E.A. (1980)Atherosclerosis 36, 589–593.
Kudzma, D.J., Swaney, J.B., and Ellis, E.N. (1979)Biochim. Biophys. Acta 572, 257–268.
Kruski, A.W., and Scanu, A.M. (1975)Biochim. Biophys. Acta 409, 26–38.
Dashti, N., Kelley, J.L., Thayer, R.H., and Ontko, J.A. (1983)J. Lipid Res. 24, 368–382.
Poernama, F., Schreyer, S.A., Bitgood, J.J., Cook, M.E., and Atti, A.D. (1990)J. Lipid Res. 31, 955–963.
Chan, L., Jackson, R.L., and Means, A.R. (1978)Circulation Res. 43, 209–217.
Eisenberg, S. (1984)J. Lipid Res. 25, 1017–1058.
Fidge, N., Nestel, P., Ishikawa, T., Reardon, M., and Billington, T. (1980)Metabolism 29, 643–653.
Tall, A.R. (1986)J. Lipid Res. 27, 361–367.
Author information
Authors and Affiliations
About this article
Cite this article
Cho, B.H.S., Park, J.R. Compositional changes and apoprotein A-I metabolism of plasma high density lipoprotein in estrogenized chicks. Lipids 26, 819–823 (1991). https://doi.org/10.1007/BF02536163
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02536163